Belgium· BE-AMP-SAM599493-00
Uplizna 100 mg
A inebilizumab product containing inebilizumab, registered in Belgium by Amgen Europe. The same ATC class is registered in 8 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Inebilizumab is registered in 8 of 19 countries.
Countries holding a registration under ATC L04AG10 (inebilizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 5 of them publish a price we can compare per daily dose
Inebilizumab · ATC L04AG10
8 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Netherlands
- Norwayprice
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Inebilizumab
- Manufacturer
- Amgen Europe
- Country
- Belgium (BE)
- ATC code
- L04AG10
- ATC class
- Inebilizumab
- Defined daily dose
- 1.67 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
51 interactions on record for inebilizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Inebilizumab · interactions on record
51 records
- 27 severe
- 18 moderate
- 6 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Inebilizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaUPLIZNAAmgen Europe B.V., Breda
- FinlandUpliznaAmgen Europe B.V.
- IrelandUplizna 100 mg concentrate for solution for infusionAmgen Europe B.V.,
- NorwayUpliznaAmgen Europe B.V.
- PolandUpliznaAmgen Europe B.V.
- SwedenUplizna 100 mg Koncentrat till infusionsvätska, lösningAmgen Europe B.V.
- CanadaUPLIZNAAMGEN CANADA INC
- SwitzerlandUplizna 100 mg/10ml, Konzentrat zur Herstellung einer InfusionslösungAmgen Switzerland AG
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Uplizna
- Norway · Uplizna
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/35d56917-2907-4155-b196-dc16b53246b5 GET /v1/drugs/35d56917-2907-4155-b196-dc16b53246b5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Uplizna 100 mg",
"name_fr": "Uplizna 100 mg",
"name_nl": "Uplizna 100 mg",
"amp_code": "SAM599493-00",
"strengths": [
"10.0000",
"10.0000",
"10.0000",
"1.6100"
],
"pack_count": 1,
"substances": [
"Inebilizumab",
"Polysorbate 80",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Inebilizumab",
"authorisation_numbers": [
"EU/1/21/1602/001"
]
}See everything about inebilizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.